烟台正海生物科技股份有限公司 2018 年第三季度报告全文 烟台正海生物科技股份有限公司 公司负责人王涛、主管会计工作负责人赵丽及会计机构负责人(会计主管人 员)赵丽声明：保证季度报告中财务报表的真实、准确、完整。 2 烟台正海生物科技股份有限公司 2018 年第三季度报告全文 2018 年第三季度报告 2018-051 2018 年 10 月 1 烟台正海生物科技股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 563,251,863.08 | 530,816,041.73 | | 6.11% | | 归属于上市公司股东的净资产 | 50 ...

[Important Notice](index=2&type=section&id=Item%201.%20Important%20Notice) The company's board of directors, supervisory board, and all senior management ensure the truthfulness, accuracy, and completeness of this quarterly report, with all directors confirming attendance at the review meeting - The company's board of directors, supervisory board, and directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions, and assume individual and joint legal liabilities[3](index=3&type=chunk) - All directors attended the board meeting that reviewed this quarterly report[4](index=4&type=chunk) - The company's principal, chief financial officer, and head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial statements in the quarterly report[4](index=4&type=chunk) [Company Profile](index=3&type=section&id=Item%202.%20Company%20Profile) This section provides an overview of the company's key financial data, significant risks, and shareholder structure [Key Accounting Data and Financial Indicators](index=3&type=section&id=Item%202.%20I.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2018, the company achieved strong performance with total operating revenue increasing by **28.79%** to **47.18 million Yuan**, and net profit attributable to shareholders surging by **181.29%** to **21.88 million Yuan** 2018 Q1 Key Financial Indicators | Indicator | Current Period | Prior Year Same Period | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue (Yuan) | 47,179,561.64 | 36,634,261.86 | 28.79% | | Net Profit Attributable to Shareholders of Listed Company (Yuan) | 21,882,922.72 | 7,779,602.87 | 181.29% | | Net Cash Flow from Operating Activities (Yuan) | 18,977,094.93 | 8,312,254.04 | 128.30% | | Basic Earnings Per Share (Yuan/share) | 0.27 | 0.13 | 107.69% | | Weighted Average Return on Net Assets | 4.43% | 3.35% | 1.08% | | Total Assets (Yuan) | 552,440,299.38 | 530,816,041.73 | 4.07% (vs. end of prior year) | | Net Assets Attributable to Shareholders of Listed Company (Yuan) | 505,065,885.55 | 483,182,962.83 | 4.53% (vs. end of prior year) | - During the reporting period, total non-recurring gains and losses amounted to **345,874.18 Yuan**, primarily from government grants[8](index=8&type=chunk) [Significant Risk Disclosures](index=4&type=section&id=Item%202.%20II.%20Significant%20Risk%20Disclosures) The company faces four main risks: over-reliance on oral repair membranes and biomembranes, long and uncertain new product R&D cycles, industry regulatory and centralized procurement policy changes, and challenges in maintaining high growth rates - The company's main revenue is derived from oral repair membranes and biomembranes, posing a risk of over-concentration on leading products, which could significantly impact performance if market conditions, demand, or competition change[9](index=9&type=chunk) - New product (Class III medical devices) R&D involves substantial investment, multiple stages, and long cycles, with uncertainty from R&D to approval, constituting a new product R&D risk[11](index=11&type=chunk) - Healthcare system reforms, including centralized procurement and tender price reductions, along with increasingly strict medical device regulations, pose industry regulatory and policy change risks to the company[12](index=12&type=chunk) - The company faces growth risks, requiring continuous improvement in strategy, management, technology, and market development to maintain high growth and address potential adverse changes[13](index=13&type=chunk) [Shareholder Information](index=5&type=section&id=Item%202.%20III.%20Total%20Number%20of%20Shareholders%20and%20Shareholding%20of%20Top%20Ten%20Shareholders%20at%20Period-End) As of the end of the reporting period, the company had **9,036 common shareholders**, with controlling shareholder Mi Bohai holding **42.53%**, indicating a relatively concentrated equity structure among the top ten shareholders - As of the end of the reporting period, the company had **9,036 common shareholders**[16](index=16&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage | Number of Shares | Nature | | :--- | :--- | :--- | :--- | | Mi Bohai | 42.53% | 34,020,000 | Domestic Natural Person | | Longwood Biotechnologies Inc. | 14.85% | 11,880,000 | Overseas Legal Entity | | Beijing Dinghui Weixin Venture Capital Center | 5.31% | 4,248,000 | Domestic Non-State-Owned Legal Entity | | Blue Economic Zone Industrial Investment Fund | 3.75% | 3,000,000 | Domestic Non-State-Owned Legal Entity | | Beijing Dinghui Weisen Venture Capital Center | 3.69% | 2,952,000 | Domestic Non-State-Owned Legal Entity | | Jiaxing Zhenghe Venture Capital Partnership | 3.38% | 2,700,000 | Domestic Non-State-Owned Legal Entity | | Yantai Innovation and Entrepreneurship Investment Co., Ltd. | 1.50% | 1,200,000 | Domestic Non-State-Owned Legal Entity | | China Cinda International Trust Co., Ltd. | 0.51% | 410,000 | Domestic Non-State-Owned Legal Entity | | Wang Manyun | 0.40% | 319,000 | Domestic Natural Person | | Shi Yuqing | 0.31% | 246,000 | Domestic Natural Person | [Significant Matters](index=7&type=section&id=Item%203.%20Significant%20Matters) This section details major changes in financial data, business performance, use of raised funds, dividend policy, and future performance forecasts [Analysis of Significant Changes in Key Financial Data](index=7&type=section&id=Item%203.%20I.%20Significant%20Changes%20in%20Key%20Financial%20Data%20and%20Reasons) Multiple financial indicators showed significant changes during the reporting period, with substantial increases in operating profit and net profit driven by improved performance, while balance sheet changes relate to wealth management product purchases and land use rights capitalization Significant Changes in Financial Statement Items and Reasons | Financial Statement Item | YoY Change | Reason | | :--- | :--- | :--- | | Cash and Cash Equivalents | -30.63% | Primarily due to increased funds used for purchasing wealth management products during the reporting period | | Intangible Assets | 149.75% | Primarily due to capitalization of land use rights for the West District project during the reporting period | | Other Non-Current Assets | -92.58% | Primarily due to capitalization of land use rights for the West District project during the reporting period | | Administrative Expenses | -31.79% | Primarily due to reduced R&D expenses and share-based payment expenses during the reporting period | | Investment Income | N/A | Primarily due to adjustment of bank wealth management income to this account during the reporting period | | Operating Profit | 221.13% | Primarily due to increased performance during the reporting period | | Net Profit | 181.29% | Primarily due to increased performance during the reporting period | | Net Cash Flow from Investing Activities | 3436.85% | Primarily due to purchasing wealth management products with idle funds during the reporting period | [Business Review and Outlook](index=8&type=section&id=Item%203.%20II.%20Business%20Review%20and%20Outlook) During the reporting period, the company's operating revenue increased by **28.78%** and net profit by **181.29%**, primarily driven by a **61.60%** growth in distribution model revenue and increased market expansion efforts Revenue by Sales Model | Sales Model | Sales Revenue (Ten Thousand Yuan) | YoY Change | | :--- | :--- | :--- | | Direct Sales | 1,276.46 | -16.82% | | Distribution | 3,440.22 | 61.60% | Production and Sales Overview | Item | Current Period | Prior Year Same Period | YoY Change | | :--- | :--- | :--- | :--- | | Sales Volume (pieces/bottles) | 53,135 | 31,321 | 69.65% | | Production Volume (pieces/bottles) | 66,065 | 38,944 | 69.64% | | Inventory (pieces/bottles) | 49,864 | 37,194 | 34.06% | [Use of Raised Funds](index=9&type=section&id=Item%203.%20V.%20Comparison%20Table%20of%20Use%20of%20Raised%20Funds) The company's total raised funds are **191.71 million Yuan**, with **0.81 million Yuan** invested this quarter and a cumulative investment of **4.86 million Yuan**, primarily for three projects currently in early construction stages and not yet generating benefits Progress of Raised Fund Investment Projects | Committed Investment Project | Committed Investment Amount (Ten Thousand Yuan) | Cumulative Investment Amount as of Period-End (Ten Thousand Yuan) | Investment Progress | | :--- | :--- | :--- | :--- | | Bio-regenerative Materials Industrial Base Upgrade Project | 9,745.79 | 93.48 | 0.96% | | R&D Center Construction Project | 6,500 | 244.36 | 3.76% | | Marketing Network and Informatization Construction Project | 2,925.12 | 148.44 | 5.07% | | **Total** | **19,170.91** | **486.28** | **--** | - All committed investment projects are in the construction phase and have not yet met planned progress or expected returns[27](index=27&type=chunk) - Unused raised funds are partly used for purchasing principal-protected wealth management products, with the remainder held in special raised fund accounts[27](index=27&type=chunk) [Execution of Cash Dividend Policy](index=10&type=section&id=Item%203.%20VI.%20Execution%20of%20Cash%20Dividend%20Policy%20During%20the%20Reporting%20Period) The company's 2017 profit distribution plan proposes a cash dividend of **5.00 Yuan (tax inclusive) per 10 shares**, totaling **40 million Yuan**, which was approved by the annual general meeting of shareholders on April 24, 2018 - The company's board of directors approved the 2017 profit distribution plan on March 29, 2018, proposing a cash dividend of **5.00 Yuan (tax inclusive) per 10 shares** based on a total share capital of 80,000,000 shares, totaling **40,000,000.00 Yuan**[28](index=28&type=chunk) - This profit distribution plan was approved by the company's 2017 annual general meeting of shareholders on April 24, 2018[28](index=28&type=chunk)[29](index=29&type=chunk) [Semi-Annual Performance Forecast](index=11&type=section&id=Item%203.%20VII.%20Warning%20and%20Explanation%20of%20Possible%20Loss%20or%20Significant%20Change%20in%20Cumulative%20Net%20Profit%20from%20Beginning%20of%20Year%20to%20End%20of%20Next%20Reporting%20Period%20Compared%20to%20Same%20Period%20Last%20Year) The company forecasts net profit attributable to shareholders for H1 2018 to be between **38.64 million Yuan** and **40.73 million Yuan**, representing an **85% to 95%** year-on-year increase, driven by sales growth, lower expense ratios, and increased investment income - The estimated net profit attributable to shareholders of the listed company for January-June 2018 is between **38.6417 million Yuan** and **40.7304 million Yuan**, representing a year-on-year increase of **85% to 95%**[30](index=30&type=chunk) - Key reasons for performance growth include: (1) increased market expansion leading to higher product sales; (2) a decrease in the proportion of sales and administrative expenses to operating revenue compared to the same period last year; and (3) a significant increase in wealth management income compared to the same period last year[30](index=30&type=chunk) [Other Significant Matters](index=9&type=section&id=Other%20Significant%20Matters) During the reporting period, the company had no overdue unfulfilled commitments, no irregular external guarantees, and no non-operating appropriation of company funds by controlling shareholders or their related parties - The company had no overdue unfulfilled commitments by the actual controller, shareholders, related parties, acquirers, or the company itself during the reporting period[24](index=24&type=chunk) - The company had no irregular external guarantees during the reporting period[31](index=31&type=chunk) - There was no non-operating appropriation of company funds by controlling shareholders or their related parties during the reporting period[32](index=32&type=chunk) [Financial Statements](index=12&type=section&id=Item%204.%20Financial%20Statements) This section presents the company's consolidated and parent company balance sheets, income statements, and cash flow statements as of March 31, 2018 [Financial Statements](index=12&type=section&id=Item%204.%20I.%20Financial%20Statements) This section provides the consolidated and parent company balance sheets, income statements, and cash flow statements as of March 31, 2018, showing steady asset growth to **552.44 million Yuan**, significant net profit increase, but slower operating cash flow growth and substantial investment cash outflow due to wealth management product purchases Consolidated Balance Sheet Summary (2018-03-31) | Item | Period-End Balance (Yuan) | Period-Beginning Balance (Yuan) | | :--- | :--- | :--- | | Total Assets | 552,440,299.38 | 530,816,041.73 | | Total Liabilities | 47,374,413.83 | 47,633,078.90 | | Total Equity Attributable to Parent Company Owners | 505,065,885.55 | 483,182,962.83 | Consolidated Income Statement Summary (Q1 2018) | Item | Amount Incurred in Current Period (Yuan) | Amount Incurred in Prior Period (Yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 47,179,561.64 | 36,634,261.86 | | Operating Profit | 25,900,215.09 | 8,065,271.17 | | Net Profit | 21,882,922.72 | 7,779,602.87 | | Basic Earnings Per Share | 0.27 | 0.13 | Consolidated Cash Flow Statement Summary (Q1 2018) | Item | Amount Incurred in Current Period (Yuan) | Amount Incurred in Prior Period (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 18,977,094.93 | 8,312,254.04 | | Net Cash Flow from Investing Activities | -49,204,615.55 | -1,391,200.35 | | Net Cash Flow from Financing Activities | 0.00 | 0.00 | | Net Increase in Cash and Cash Equivalents | -30,227,520.62 | 6,921,053.69 | [Audit Report](index=25&type=section&id=Item%204.%20II.%20Audit%20Report) The company's 2018 first-quarter report is unaudited - The company's first-quarter report is unaudited[58](index=58&type=chunk)

烟台正海生物科技股份有限公司 2017 年年度报告全文 烟台正海生物科技股份有限公司 2017 年年度报告 2018-008 2018 年 03 月 1 烟台正海生物科技股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人秘波海、主管会计工作负责人赵丽及会计机构负责人(会计主管 人员)赵丽声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、主要产品较为集中的风险 公司专注于再生医学相关产品的研发及产业化，凭借自主创新的核心技术 开发出口腔修复膜、生物膜、骨修复材料等生物再生材料，完成产品注册并上 市销售。同时，公司结合市场需求及自身技术积淀，相继启动了活性生物骨、 引导组织再生膜、新一代生物膜等新产品的梯队研发。虽然公司在销产品和在 研产品储备充足，但目前公司主要收入仍来源于口腔修复膜和生物膜。尽管公 司拥有丰富的在研产品，其中活性生物骨、引导组织再生膜等处于临床试验阶 段，新一代生物膜 ...

烟台正海生物科技股份有限公司 2017 年第三季度报告全文 2017 年 10 月 1 烟台正海生物科技股份有限公司 2017 年第三季度报告全文 烟台正海生物科技股份有限公司 2017 年第三季度报告 烟台正海生物科技股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秘波海、主管会计工作负责人赵丽及会计机构负责人(会计主管 人员)赵丽声明：保证季度报告中财务报表的真实、准确、完整。 2 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | --- | | 总资产（元） | 502,106,093.93 | | 259,137,852.25 | | 93.76% | | 归属于上市公司股东的净资产 | ...

烟台正海生物科技股份有限公司 2017 年半年度报告全文 烟台正海生物科技股份有限公司 2017 年半年度报告 2017 年 08 月 1 烟台正海生物科技股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人秘波海、主管会计工作负责人赵丽及会计机构负责人（会计主 管人员）赵丽声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、主要产品较为集中的风险 公司专注于再生医学相关产品的研发及产业化，凭借自主创新的核心技术 开发出口腔修复膜、生物膜、骨修复材料等生物再生材料，完成产品注册并上 市销售。同时，公司结合市场需求及自身技术积淀，相继启动了活性生物骨、 引导组织再生膜、新一代生物膜等新产品的梯队研发。虽然公司在销产品和在 研产品储备充足，但目前公司主要收入仍来源于口腔修复膜和生物膜。尽管公 司拥有丰富的在研产品，其中活性生物骨、引导组织再生膜、组织再生膜等处 于临床试验阶段，新一 ...